Posted by Michael Wonder on 31 Oct 2021
Schedule of Pharmaceutical Benefits - 1 November 2021 update
1 November 2021 - The November 2021 issue of the Schedule of Pharmaceutical Benefits is out and now in effect.
The November issue of the Schedule includes a few new/revised listings:
- Abemaciclib (Verzenio) - new indication
- Bortezomib (Bortezomib Juno) - new strength
- Budesonide with eformoterol fumarate dihydrate and glycopyrronium bromide (Breztri Aerosphere) - new combination product
- Daratumumab with hyaluronidase (Darzalex) - new formulation
- Darolutamide (Nubeqa) - new medicine
- Triptorelin embonate (Diphereline) - new indication
